Skip to Main Navigation
Skip to Page Content
Share This:
https://ntp.niehs.nih.gov/go/17757

TDMS Study 93021-06 Pathology Tables

NTP Experiment-Test: 93021-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01
Route: SKIN APPLICATION                                                                                           Time: 11:05:09

                                                          Final#1/Mice




       Facility:  BIORELIANCE

       Chemical CAS #:  538-75-0

       Lock Date:  02/24/00

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 93021-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 11:05:09  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.75         1.5          3.0          6.0          12.0            
                                                                MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                                                        2                         7           
    Natural Death                                                                             1            1            1           
  Survivors                                                                                                                         
    Terminal Sacrifice                                15           15           15           12           14            7           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Mesentery                                                                                 (1)                                    
      Lymphoma Malignant                                                                      1 (100%)                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 93021-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 11:05:09  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.75         1.5          3.0          6.0          12.0            
                                                                MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node, Mandibular                             (15)         (15)         (14)         (14)         (14)         (14)         
      Histiocytic Sarcoma                                                                                  1 (7%)                   
   Lymph Node, Mesenteric                             (14)         (15)         (15)         (15)         (14)         (14)         
      Histiocytic Sarcoma                                                                                  1 (7%)                   
   Lymph Node, Mediastinal                            (14)         (15)         (15)         (12)         (13)         (13)         
      Histiocytic Sarcoma                                                                                  1 (8%)                   
      Lymphoma Malignant                                                                      1 (8%)                                
   Thymus                                             (15)         (15)         (15)         (15)         (14)         (13)         
      Histiocytic Sarcoma                                                                                  1 (7%)                   
      Lymphoma Malignant                                                                      1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (14)         (15)         
      Lymphoma Malignant                                                                      1 (7%)                                
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 93021-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 11:05:09  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.75         1.5          3.0          6.0          12.0            
                                                                MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Histiocytic Sarcoma                                                                                  1 (7%)                   
      Lymphoma Malignant                                                                      1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 93021-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 11:05:09  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.75         1.5          3.0          6.0          12.0            
                                                                MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)                                                 1           1                           
     Total Primary Neoplasms                                                                1           1                           
                                                                                                                                    
   Total Animals with Benign Neoplasms                                                                                              
     Total Benign Neoplasms                                                                                                         
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                   1           1                           
     Total Malignant Neoplasms                                                              1           1                           
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------